TCL Archive Center Core Grants Picture Less Bleak; Competing Renewals To Receive 50% Of Recommended Increases January 4, 1980
TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive New Treatment Projects Get Go-Ahead; Groups Competition To Be Increased, VA Studies Face Cut November 4, 1977